10-Q: AEON Biopharma Shifts Strategy, Secures Funding Amid Losses

AEON Biopharma reported continued operating losses and a strategic pivot to a Botox biosimilar pathway, securing new financing while addressing going concern doubts and NYSE American listing compliance.

Summary

• AEON Biopharma reported a net loss of $2.1 million for the nine months ended September 30, 2025, compared to a net income of $39.9 million for the same period in 2024.
• The company's accumulated deficit increased to $433.7 million as of September 30, 2025.
• Cash and cash equivalents significantly increased to $5.9 million as of September 30, 2025, from $13 thousand at December 31, 2024.
• A strategic reprioritization was announced on July 9, 2024, to pursue a Section 351(k) biosimilar regulatory pathway for ABP-450, using AbbVie Inc.'s Botox as a reference product, following the discontinuation of Phase 2 clinical trials for migraine due to unmet endpoints in May 2024.
• Initial analytical studies for the biosimilar program show a 100% amino acid sequence match between ABP-450 and Botox, with highly similar potency across two distinct assays.
• The company held an initial meeting with the FDA in Q3 2024 and has a confirmed Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA on November 19, 2025, to review analytical study results.
• AEON raised approximately $18.3 million in net proceeds from a public offering in January 2025.
• A private placement (PIPE) financing agreement was entered into on November 12, 2025, for $6 million in gross proceeds, with a first closing of $1.79 million expected in November 2025.
• A binding term sheet was signed with Daewoong on November 13, 2025, to exchange $15.0 million in principal plus accrued interest of 2024 Convertible Notes for approximately 23.1 million shares of Class A common stock, a new $1.5 million convertible note, and approximately 8 million cash-exercise warrants, subject to stockholder approval.
• The company received a notice of non-compliance from NYSE American regarding its stockholders' equity and has until August 3, 2026, to regain compliance.
• A lawsuit with Odeon Capital Group LLC was settled on October 31, 2025, for $1.0 million cash, $0.3 million in common stock, and 125,000 warrants, resulting in a $0.4 million gain on settlement.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses, a substantial accumulated deficit, and a going concern warning. While recent financing efforts and a strategic pivot to a biosimilar pathway offer some hope, the failure of previous clinical trials and ongoing listing compliance issues indicate a high level of risk and uncertainty. The positive analytical results for the biosimilar program are a good sign, but the path to commercialization is long and capital-intensive.

Positives

• Successfully completed a public offering in January 2025, raising $18.3 million in net proceeds.
• Secured additional financing through a PIPE agreement for $6 million gross proceeds, with a first closing of $1.79 million expected in November 2025.
• Reached a binding term sheet with Daewoong to exchange $15.0 million in convertible notes for equity and a new convertible note, which could improve the balance sheet structure.
• Initial analytical studies for the ABP-450 biosimilar program show promising results, including a 100% amino acid sequence match with Botox and highly similar potency.
• The company has aligned with the FDA on next steps for the Botox biosimilar pathway and has a confirmed BPD Type 2a meeting on November 19, 2025.
• Settled a legal proceeding with Odeon Capital Group LLC for $1.0 million cash, $0.3 million in common stock, and 125,000 warrants, resulting in a $0.4 million gain.
• Reduced Selling, General and Administrative (SG&A) expenses by $2.7 million (25%) and Research and Development (R&D) expenses by $8.7 million (80%) for the nine months ended September 30, 2025, compared to the prior year, reflecting cash preservation measures.
• The company expects to have sufficient cash to fund its operating plan into the second quarter of 2026, including anticipated PIPE financing funds.

Negatives

• Reported a net loss of $2.1 million for the nine months ended September 30, 2025, and $4.5 million for the three months ended September 30, 2025.
• Accumulated deficit increased to $433.7 million as of September 30, 2025.
• Phase 2 clinical trials for episodic and chronic migraine with ABP-450 did not meet primary or secondary endpoints, leading to their discontinuation in May 2024.
• The company has experienced recurring losses from operations and negative cash flows from operations since inception.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern.
• Received a notice of non-compliance from NYSE American for not meeting the minimum stockholders' equity requirement of $2.0 million, with a deadline of August 3, 2026, to regain compliance.
• Identified material weaknesses in internal control over financial reporting, including a lack of sufficient and qualified resources for complex transactions and inadequate segregation of duties.
• Incurred a $75.6 million loss on the issuance of warrants in the first quarter of 2025.
• The company's stock price decreased significantly from $38.88 at December 31, 2024, to $0.81 at September 30, 2025, impacting contingent consideration valuation.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses and negative cash flows.
• Inability to raise additional capital on commercially reasonable terms or at all, which could force the company to cease operations or reduce development programs.
• Risk of delisting from NYSE American if compliance with listing standards is not regained by August 3, 2026.
• Dependency on the clinical and commercial success of ABP-450 as a biosimilar.
• Uncertainty in obtaining regulatory approval for ABP-450 as a biosimilar.
• Reliance on Daewoong Pharmaceutical Co., Ltd. as an exclusive and sole supplier for ABP-450, with risks of termination or loss of significant rights under the Daewoong Agreement.
• Potential for dilution of existing shareholders from future equity financings.
• Competition from existing competitors and new market entrants in the botulinum toxin market.
• Impact of macroeconomic developments beyond control, such as health epidemics, economic uncertainties, or natural disasters.
• Material weaknesses in internal control over financial reporting could lead to material misstatements.
• The termination purchase right in the Daewoong Agreement allows Daewoong to purchase all Know-How related to ABP-450 for $1.00 under certain termination conditions.

Future Outlook

The company expects to incur losses and use cash in its operations for the foreseeable future. It plans to use net proceeds from recent and anticipated financings to further advance analytical work for its ABP-450 biosimilar program and for general corporate purposes. The company anticipates increased R&D expenses as it pursues the biosimilar pathway and any necessary clinical studies, which will be significant over the next few years. It also expects SG&A expenses to decrease in the near future to focus resources on R&D, but then increase with commercialization efforts if regulatory approval is obtained. The company expects to have sufficient cash to fund its operating plan into the second quarter of 2026, including funds from the PIPE financing.

Management Comments

• "We are a biopharmaceutical company seeking accelerated and full-label United States (U.S.) market entry by developing our ABP-450 as a BOTOX biosimilar for debilitating medical conditions."
• "We plan to develop and seek regulatory approval of ABP-450 as a biosimilar product in the U.S. through submission of a Biologics License Application, (BLA), under Section 351(k) of the Public Health Service Act, (Section 351(k) BLA) with the ultimate goal of addressing the global therapeutic botulinum toxin market, which we estimate to be at least $3.3 billion based on AbbVie's reported global revenues for its therapeutic Botox segment for the fiscal year ended 2024."
• "The initial results from our analytical studies indicate a 100% amino acid sequence match confirmed between ABP-450 and Botox, based on sequence coverage of 93% to 99% for the five proteins that comprise the 900kD botulinum toxin type A complex, using liquid chromatography/mass spectrometry (LC/MS) analysis of more than 3,400 peptides across multiple lots of ABP-450 and Botox, without any sequence deviations observed."
• "ABP-450 also demonstrated highly similar potency across two distinct assays (LD50 in vivo biological activity and CBPA cell-based potency assay) to support clinical dose predictability, comparable vial to vial active ingredient composition using ELISA further supporting dose similarity and reliability, and functional cleavage of SNAP-25, consistent with the mechanism of action."
• "If we are successful in obtaining a BLA under Section 351(k) for therapeutic indications of ABP-450, the ASP for ABP-450 would be calculated using only therapeutic sales, which we believe would facilitate consistent and favorable product reimbursement to physicians when they choose to use ABP-450 for therapeutic treatments, as well as the ability to provide payors and/or providers with rebates and other financial incentives."
• "This pricing model would be unique to us within the current therapeutic neurotoxin market, and we believe it would allow physicians to provide treatment with ABP-450 at a more competitive or the same net price as the market leader after rebates and discounts."
• "As a result of these conditions, management has concluded that substantial doubt about our ability to continue as a going concern exists..."
• "As of the date of this Report, we expect to have sufficient cash to fund our operating plan into the second quarter of 2026, including funds anticipated to be received from the first and second closings of the PIPE Financing in November 2025."

Industry Context

AEON Biopharma is targeting the global therapeutic botulinum toxin market, estimated at $3.3 billion based on AbbVie's Botox revenues. The company's strategic shift to a biosimilar pathway under Section 351(k) aims to leverage the established market for Botox while potentially gaining a competitive advantage through a unique pricing model. By seeking a BLA exclusively for therapeutic indications, AEON hopes to avoid the dilution of average selling price (ASP) caused by cosmetic sales, which could lead to more favorable reimbursement for physicians and better competitive positioning against market leaders like AbbVie's Botox. This strategy is a direct response to the failure of its previous Phase 2 migraine trials, indicating a pivot towards a more de-risked regulatory pathway.

Comparison to Industry Standards

• ABP-450 is being developed as a biosimilar to AbbVie Inc.'s product Botox, which is a market leader in the therapeutic botulinum toxin market, estimated at $3.3 billion globally.
• Initial analytical studies show ABP-450 has a 100% amino acid sequence match with Botox and highly similar potency across two distinct assays (LD50 and CBPA), supporting its biosimilarity claim.
• The company's strategy to pursue a BLA under Section 351(k) exclusively for therapeutic indications aims to differentiate its pricing model from existing botulinum toxins, including Botox, which are approved under a single BLA for both therapeutic and cosmetic uses. This could allow for a more competitive or equivalent net price after rebates and discounts compared to the market leader.
• ABP-450 is already approved as a biosimilar in Mexico, India, and the Philippines, and for cosmetic uses (Jeuveau/Nuceiva) in the U.S., Canada, and the EU, demonstrating prior regulatory success for the same botulinum toxin complex.

Management Changes

Corporate Governance

Legal Proceedings

• Settled a lawsuit with Odeon Capital Group LLC on October 31, 2025, for $1.0 million in cash, $0.3 million in common stock shares, and 125,000 warrants. The lawsuit, filed on September 18, 2023, alleged failure to pay a deferred underwriting fee of $1.25 million.

Related Party Transactions

• Daewoong Pharmaceutical Co., LTD. is a related party due to the license and supply agreement for ABP-450 and the issuance of $15.0 million in convertible notes. The fair value of these notes, including the related party amount, was $17.051 million as of September 30, 2025.
• A binding term sheet was entered into with Daewoong on November 13, 2025, contemplating the exchange of the 2024 Convertible Notes for approximately 23.1 million shares of Class A common stock, a new $1.5 million convertible note, and approximately 8 million cash-exercise warrants, subject to stockholder approval.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity financings (public offering, ATM, PIPE, Daewoong exchange). The reverse stock split (1-for-72) also impacted share count. The going concern warning and NYSE American non-compliance pose risks to investment value and liquidity.
• Employees have seen headcount reductions in the prior year to preserve cash. Stock-based compensation is a significant component of compensation, with new cash-settled RSUs approved.
• Creditors, particularly Daewoong as a convertible noteholder, are impacted by the proposed exchange of notes for equity and a new note, altering their financial exposure and rights.
• Customers/Patients could potentially benefit from the strategic pivot to a biosimilar pathway for ABP-450, which aims to bring a potentially more affordable therapeutic botulinum toxin to market by improving access and potentially reducing costs through a unique pricing model.

Next Steps

• Conduct additional analyses for the ABP-450 biosimilar program.
• Attend the confirmed Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA on November 19, 2025, to review analytical study results.
• Secure additional capital to fund operations and further development of ABP-450.
• Enter into definitive documentation for the exchange of Daewoong 2024 Convertible Notes.
• Obtain stockholder approval for the Daewoong convertible notes exchange and the second closing of the PIPE financing.
• Implement and maintain effective internal controls to remediate identified material weaknesses.
• Take all reasonable measures to regain compliance with NYSE American listing standards by August 3, 2026.
• Potentially establish sales, marketing, and commercialization functions in advance of future regulatory approvals.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by recurring losses, a substantial accumulated deficit, and a "going concern" warning. The failure of key Phase 2 clinical trials for migraine forced a strategic pivot, which, while potentially promising, is a long and capital-intensive path with no guarantee of success. The NYSE American non-compliance adds significant regulatory risk, and ongoing dilution from multiple capital raises further erodes shareholder value. While the biosimilar approach and initial analytical results are positive, the company's current financial state and operational risks outweigh these early-stage positives, making it a highly speculative and risky investment. A seasoned investor would likely view the current situation as too precarious, with a high probability of further value erosion or even cessation of operations if additional capital cannot be secured on favorable terms.

Keywords

AEON Biopharma, ABP-450, Botox biosimilar, biopharmaceutical, SEC filing, 10-Q, clinical trials, migraine, cervical dystonia, FDA, Section 351(k), Daewoong, convertible notes, PIPE financing, NYSE American, going concern, warrants, financial results, biotech, drug development